App-Quantinova.ai

Real-world evidence in patient-related outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate plus prednisone (AA+P).

Geoffrey Gotto - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

Personalized risk stratification for patients with early prostate cancer (PRONTO): A Canadian team biomarker project.

David Monty Berman - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Comprehensive and epidemiological characterization of urachal adenocarcinoma: A pan-Canadian collaboration.

Belkaid Wiam - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Clinical features and outcomes of secondary somatic malignancy (SSM) arising from teratoma in late relapse germ cell tumor (GCT).

Nathan Colin Wong - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Germ cell tumor

N/A

Persistence of platinum in semen of cisplatin-treated survivors of advanced testicular cancer.

Eoghan Ruadh Malone - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Testicular cancer

Cisplatin

Excellent outcomes in bilateral testicular germ cell tumors over four decades.

Ning-Ning Lu - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Testicular cancer

N/A

Validation of plasma miR-371a-3p expression in patients with metastatic and early stage germ cell tumor.

Lucia Nappi - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Germ cell tumor

N/A

Clinical features and outcomes of secondary somatic malignancy (SSM) associated with primary mediastinal nonseminomatous germ cell tumors (PM-NSGCT).

Lucas W. Dean - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Germ cell tumor

N/A

Validation of a genomic classifier to predict adverse pathology in men diagnosed with low risk prostate cancer.

Hyung Lae Kim - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study.

Thomas Powles - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic Renal Cell Cancer

Pembrolizumab

Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).

Toni K. Choueiri - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic Renal Cell Cancer

Sunitinib

Nivolumab demonstrates benefit over nomogram-predicted 12-month survival as salvage therapy for metastatic urothelial carcinoma.

Gregory Russell Pond - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B.

David F. McDermott - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Clear cell renal carcinoma

Pembrolizumab

Can free PSA be used as a biomarker in biochemical recurrence after surgery to predict castrate resistant prostate cancer?

Hanan Goldberg - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabozantinib for metastatic castration-resistant prostate cancer (mCRPC) following docetaxel: Combined analysis of two phase III trials.

Gregory Russell Pond - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabozantinib

Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214.

David F. McDermott - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic Renal Cell Cancer

Ipilimumab

Impact of body mass index (BMI) on treatment outcomes to immune checkpoint blockade (ICB) in metastatic renal cell carcinoma (mRCC).

Aly-Khan A. Lalani - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic Renal Cell Cancer

N/A

Efficacy of targeted therapy (TT) after checkpoint inhibitors (CPI) in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).

Austin Kalirai - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic Renal Cell Cancer

N/A

Determining biomarkers of response to docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC) using circulating cell-free tumor DNA (ctDNA).

Daniel Khalaf - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Docetaxel

Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N+I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214.

Nizar M. Tannir - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic Renal Cell Cancer

Ipilimumab

Filters

28841 Abstracts